Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097958 | 0.88 | HSD17B10 (0.46) | HSD17B10HPGDPTGS1AKR1C3AKR1C2 | |
| SCHEMBL10624636 | 0.87 | HSD17B10 (0.49) | HSD17B10HPGDPTGS1AKR1C3AKR1C2 | |
| SCHEMBL2742615 | 0.85 | HSD17B10 (0.68) | HSD17B10HPGDPTGS1AKR1C3AKR1C2 | |
| SCHEMBL898733 | 0.83 | HPGD (0.52) | HSD17B10HPGDPTGS1AKR1C3AKR1C2 | |
| Bromide SCHEMBL29853696 | 0.83 | HSD17B10 (0.66) | HSD17B10HPGDPTGS1AKR1C3AKR1C2 | |
| SCHEMBL29853520 | 0.83 | HPGD (0.52) | HSD17B10HPGDPTGS1AKR1C3AKR1C2 | |
| SCHEMBL16836022 | 0.81 | HSD17B10 (0.50) | HSD17B10PTGS1AKR1C3AKR1C2POLB | |
| SCHEMBL30660236 | 0.81 | HSD17B10 (0.73) | HSD17B10 | |
| SCHEMBL892777 | 0.81 | HSD17B10 (0.73) | HSD17B10 | |
| SCHEMBL8237110 | 0.81 | HSD17B10 (0.50) | HSD17B10PTGS1AKR1C3AKR1C2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153808-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2382192-A2 | DIHYDROPYRIDONE AMIDES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072647-A2 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160387-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| EP-1567477-B1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-2090566-A2 | Certain phenylacetic acids and derivatives | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| EP-1567477-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | Novartis AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | HSD17B10 68/4885HPGD 84/4885PTGS1 7/4885 |
| US-20100160387-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | HSD17B10 4331/4885HPGD 891/4885PTGS1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.